OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 4,000 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 4,000 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $25.75, for a total transaction of $103,000.00. Following the sale, the director owned 6,897,764 shares of the company’s stock, valued at approximately $177,617,423. This represents a 0.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

OrthoPediatrics Price Performance

Shares of OrthoPediatrics stock opened at $24.03 on Thursday. The company has a market cap of $627.42 million, a PE ratio of -14.30 and a beta of 0.98. The business has a 50 day moving average of $21.23 and a 200 day moving average of $18.58. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, equities research analysts forecast that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on KIDS. Needham & Company LLC raised their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. BTIG Research increased their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 20th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $26.44.

OrthoPediatrics News Summary

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during a limited release. The company said the system addresses pediatric hip trauma and deformities, improves fixation and surgical workflow, and is the first of several planned systems in a broader plating portfolio. The launch provides a potential long-term revenue and market-share opportunity, although the company did not provide specific financial guidance. OrthoPediatrics Announces Full Commercial Launch of 3P Pediatric Plating Platform Hip System
• Neutral Sentiment: Reported short interest was listed as zero shares with a zero-day short-interest ratio. However, the filing data also showed an invalid “NaN” change, making the statistic unreliable and providing little usable insight into potential short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholder entities associated with Squadron Capital and Jennifer N. Pritzker reported sales totaling 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The transactions reduced the reported position by only about 0.56%, leaving ownership of roughly 6.86 million shares, so the sales appear relatively small compared with the remaining stake. Nevertheless, repeated insider selling can weigh on sentiment, particularly with KIDS trading near its 52-week high. SEC insider transaction filing

Hedge Funds Weigh In On OrthoPediatrics

Several large investors have recently added to or reduced their stakes in KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after purchasing an additional 645 shares during the period. Millennium Management LLC raised its position in shares of OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after purchasing an additional 233,873 shares during the period. Goldman Sachs Group Inc. raised its position in shares of OrthoPediatrics by 112.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after purchasing an additional 106,041 shares during the period. Jane Street Group LLC purchased a new position in shares of OrthoPediatrics during the 1st quarter valued at $389,000. Finally, American Century Companies Inc. lifted its stake in shares of OrthoPediatrics by 12.5% during the 2nd quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock valued at $741,000 after buying an additional 3,828 shares in the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.